Annalisa JenkinsAnnalisa is a biopharma thought leader with over 25 years of industry experience. She has extensive experience in building and financing biotech companies pursuing cures for the most challenging rare diseases, advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally.
Annalisa is a board member of over 10 growing companies globally. She also is a committee member of the Science Board to the U.S. FDA, a board member at Faster Cures of The Milken Institute and the Chair of The Court The London School of Hygiene and Tropical Medicine.
Previously, Annalisa has served as president and CEO of Dimension Therapeutics, a leading gene therapy company. She has also held leadership roles at Merck Serono and Bristol Myers-Squibb for over 15 years. Annalisa has a MD from St Bartholemew’s Hospital in the University of London.